Ocera Therapeutics (OCRX) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ocera Therapeutics Reports First Quarter 2016 Financial Results and Pipeline Progress
April 29, 2016 9:05 AM EDT-- Company on target to complete enrollment in STOP-HE in the fourth quarter; approximately 165 patients enrolled to date --
-- Study with orally-available OCR-002 in patients with cirrhosis to begin in the third quarter with data expected by year-end --
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., April 29, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ: OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today reported financial results for the quarter ended March 31, 2016, and provided updates to its clinical... More
